Nesvacumab
Term · Oncology and biomedicine · MLC-T-ONC-015489
A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinas e (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.
| Identifier | MLC-T-ONC-015489 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-ANG2 monoclonal antibody REGN910; anti-ANG2 MoAb REGN910 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015489",
"term": "Nesvacumab",
"field": "Oncology and biomedicine",
"definition": "A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinas e (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.",
"synonyms": [
"anti-ANG2 monoclonal antibody REGN910",
"anti-ANG2 MoAb REGN910"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/nesvacumab/"
}
Record 11,726 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.